Jinxin Fertility Group (1951.HK)

Overall impact
C (55)

Commentary

Jinxin Fertility Group is an average overall performer. With a 'C' rating of 55.2 for overall impact (52nd percentile compared to all companies), Jinxin Fertility Group ranks 30th out of 39 industry peers, behind Concord Medical Services, Sunlink Health Systems, New Frontier Health and 26 others, and ahead of Orpea, HCA Healthcare, Tenet Healthcare and 6 others. On top material causes for Jinxin Fertility Group's industry (Healthcare Providers), Jinxin Fertility Group performs well in Child and Maternal Health (80.2 score) and Improved Mental Health (95.8) and performs poorly in Quality Lifelong Education (34.5 score), Sanitation Access (39.8), No Poverty (36.9) and 2 other causes where it received a 'D' or 'F' score.
Impact
Cause 1951.HK
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Jinxin Fertility Group

Employees
3,494
Sector
Health Care
Industry
Health Care Providers & Services
Sub-industry
Health Care Facilities
SASB industry
Health Care Delivery
Headquarters
China
Share classes
1951.HK
Description
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. It primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. The company also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; obstetrics, gynecology, urology, internal medicine, and pediatrics medical services; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and engages in the investment management and management consultancy, postpartum and rehabilitation care, property investment, and real estate development and operation activities. Additionally, the company is involved in the sale of medicines, consumables, and equipment; and research and development of IVF related projects, including scientific research and related commercialization. Jinxin Fertility Group Limited was founded in 1951 and is headquartered in Chengdu, China.
Material causes
Ethos considers the following causes material for Jinxin Fertility Group, based on its industry sub-industry Health Care Facilities. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.